These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 7140531)

  • 21. Buprenorphine tablet versus liquid: a clinical trial comparing plasma levels, efficacy, and symptoms.
    Chawarski MC; Moody DE; Pakes J; O'Connor PG; Schottenfeld RS
    J Subst Abuse Treat; 2005 Dec; 29(4):307-12. PubMed ID: 16311183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of transdermal buprenorphine: a randomized, placebo-controlled trial in 289 patients with severe cancer pain.
    Poulain P; Denier W; Douma J; Hoerauf K; Samija M; Sopata M; Wolfram G
    J Pain Symptom Manage; 2008 Aug; 36(2):117-25. PubMed ID: 18411010
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overdosage of buprenorphine: case report.
    Banks CD
    N Z Med J; 1979 Apr; 89(633):255-7. PubMed ID: 286917
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A pilot study of buprenorphine-naloxone combination tablet (Suboxone) in treatment of opioid dependence.
    Bell J; Byron G; Gibson A; Morris A
    Drug Alcohol Rev; 2004 Sep; 23(3):311-7. PubMed ID: 15370011
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug absorption by sublingual and rectal routes.
    De Boer AG; De Leede LG; Breimer DD
    Br J Anaesth; 1984 Jan; 56(1):69-82. PubMed ID: 6140933
    [No Abstract]   [Full Text] [Related]  

  • 26. Buprenorphine + naloxone: new combination. Opiate dependence: no proof of reduced risk of self-administered injection.
    Prescrire Int; 2007 Dec; 16(92):232-5. PubMed ID: 18087797
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Buprenorphine abuse: high dose intravenous administration of buprenorphine].
    Varescon I; Vidal-Trécan G; Nabet N; Boissonnas A
    Encephale; 2002; 28(5 Pt 1):397-402. PubMed ID: 12386540
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Opioid addicts at admission vs. slow-release oral morphine, methadone, and sublingual buprenorphine maintenance treatment participants.
    Giacomuzzi S; Kemmler G; Ertl M; Riemer Y
    Subst Use Misuse; 2006; 41(2):223-44. PubMed ID: 16393744
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Sublingual pharmacologic absorption: mechanism and pathology].
    Martin GR
    An Esp Odontoestomatol; 1967; 26(5):410-7. PubMed ID: 5237249
    [No Abstract]   [Full Text] [Related]  

  • 30. [Evaluation of analgesic and sedative effects of a new analgesic, buprenorphine: comparison of intravenous buprenorphine and pentazocine during the immediate post-operative period (author's transl)].
    Nishioka K; Imamura T; Amaha K
    Masui; 1981 Jan; 30(1):64-9. PubMed ID: 7218511
    [No Abstract]   [Full Text] [Related]  

  • 31. Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia.
    Winstock AR; Lea T; Sheridan J
    Int J Drug Policy; 2008 Dec; 19(6):450-8. PubMed ID: 18359216
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis after intravenous injection of sublingual buprenorphine in acute hepatitis C carriers: report of two cases of disappearance of viral replication after acute hepatitis.
    Peyrière H; Tatem L; Bories C; Pageaux GP; Blayac JP; Larrey D
    Ann Pharmacother; 2009 May; 43(5):973-7. PubMed ID: 19383935
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Buprenorphine dosing regime in the management of out-patient heroin withdrawal.
    Lintzeris N
    Drug Alcohol Rev; 2002 Mar; 21(1):39-45. PubMed ID: 12189003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The use of buprenorphine in combination with loco-regional anesthesia during oro-dental surgical procedures].
    Patrignani F; Tempesta F; Favaro R; Ales G; Patrignani L
    G Anest Stomatol; 1985; 14(4):9-15. PubMed ID: 3938971
    [No Abstract]   [Full Text] [Related]  

  • 35. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials.
    Likar R; Kayser H; Sittl R
    Clin Ther; 2006 Jun; 28(6):943-52. PubMed ID: 16860176
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development and validation of a HPLC method for the determination of buprenorphine hydrochloride, naloxone hydrochloride and noroxymorphone in a tablet formulation.
    Mostafavi A; Abedi G; Jamshidi A; Afzali D; Talebi M
    Talanta; 2009 Feb; 77(4):1415-9. PubMed ID: 19084658
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of sublingual buprenorphine for pain relief in office hysteroscopy.
    Lin YH; Hwang JL; Huang LW; Chen HJ
    J Minim Invasive Gynecol; 2005; 12(4):347-50. PubMed ID: 16036196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Post-marketing surveillance of buprenorphine.
    Ray R; Pal H; Kumar R; Maulick P; Mangla R
    Pharmacoepidemiol Drug Saf; 2004 Sep; 13(9):615-9. PubMed ID: 15362084
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Crushing buprenorphine tablets.
    Muhleisen P; Spence J; Nielsen S
    Drug Alcohol Rev; 2003 Dec; 22(4):471-2. PubMed ID: 14660137
    [No Abstract]   [Full Text] [Related]  

  • 40. Transbuccal tablets of carbamazepine: formulation, release and absorption pattern.
    Giannola LI; De Caro V; Giandalia G; Siragusa MG; D'Angelo M; Lo Muzio L; Campisi G
    Int J Immunopathol Pharmacol; 2005; 18(3 Suppl):21-31. PubMed ID: 16848984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.